Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2017 - 14 Molecules with 13 Developed by Companies - Research and Markets

Research and Markets
Posted on: 17 Aug 17

The "Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

'Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2017'; Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization.

The report 'Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2017' outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 9 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Depression, Anxiety Disorders, Treatment Resistant Depression, Schizophrenia, Alzheimer's Disease, Chronic Pain, Cognitive Disorders, Epilepsy, Ischemia, Psychosis and Stroke.

Key Topics Covered:

  1. Introduction
  2. Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Overview
  3. Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Companies Involved in Therapeutics Development
  • Addex Therapeutics Ltd
  • Bristol-Myers Squibb Company
  • Denovo Biopharma LLC
  • Domain Therapeutics SA
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck & Co Inc

For more information about this report visit https://www.researchandmarkets.com/research/p3mnq7/metabotropic

View source version on businesswire.com: http://www.businesswire.com/news/home/20170817005701/en/

Business Wire
www.businesswire.com

Last updated on: 17/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.